These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
90 related articles for article (PubMed ID: 32880215)
1. Prediction of saxagliptin stability using a new approach based on Partial Least Squares and Design of Experiments. Jordan N; Zakrajšek J; Bohanec S; Roškar R; Grabnar I Pharm Dev Technol; 2020 Dec; 25(10):1260-1270. PubMed ID: 32880215 [TBL] [Abstract][Full Text] [Related]
2. Kinetic and mechanistic insight into the thermodynamic degradation of saxagliptin. Jones GS; Savage SA; Ivy S; Benitez PL; Ramirez A J Org Chem; 2011 Dec; 76(24):10332-7. PubMed ID: 22054301 [TBL] [Abstract][Full Text] [Related]
3. Development of a rapid UPLC-MS/MS method for quantification of saxagliptin in rat plasma and application to pharmacokinetic study. Gao JW; Yuan YM; Lu YS; Yao MC Biomed Chromatogr; 2012 Dec; 26(12):1482-7. PubMed ID: 22334441 [TBL] [Abstract][Full Text] [Related]
4. Synthesis and biological evaluation of all eight stereoisomers of DPP-IV inhibitor saxagliptin. Dong J; Gong Y; Liu J; Chen X; Wen X; Sun H Bioorg Med Chem; 2014 Feb; 22(4):1383-93. PubMed ID: 24457090 [TBL] [Abstract][Full Text] [Related]
5. Short-term therapy with combination dipeptidyl peptidase-4 inhibitor saxagliptin/metformin extended release (XR) is superior to saxagliptin or metformin XR monotherapy in prediabetic women with polycystic ovary syndrome: a single-blind, randomized, pilot study. Elkind-Hirsch KE; Paterson MS; Seidemann EL; Gutowski HC Fertil Steril; 2017 Jan; 107(1):253-260.e1. PubMed ID: 28228317 [TBL] [Abstract][Full Text] [Related]
6. Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin. Barnett AH; Charbonnel B; Donovan M; Fleming D; Chen R Curr Med Res Opin; 2012 Apr; 28(4):513-23. PubMed ID: 22313154 [TBL] [Abstract][Full Text] [Related]
7. Saxagliptin plus metformin combination in patients with type 2 diabetes and renal impairment. Scheen AJ Expert Opin Drug Metab Toxicol; 2012 Mar; 8(3):383-94. PubMed ID: 22313172 [TBL] [Abstract][Full Text] [Related]
8. Dapagliflozin/saxagliptin (Qtern) for type 2 diabetes. Med Lett Drugs Ther; 2018 Mar; 60(1543):55-56. PubMed ID: 29635266 [No Abstract] [Full Text] [Related]
9. Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. Deacon CF; Holst JJ Adv Ther; 2009 May; 26(5):488-99. PubMed ID: 19444391 [TBL] [Abstract][Full Text] [Related]
10. Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial. Mosenzon O; Leibowitz G; Bhatt DL; Cahn A; Hirshberg B; Wei C; Im K; Rozenberg A; Yanuv I; Stahre C; Ray KK; Iqbal N; Braunwald E; Scirica BM; Raz I Diabetes Care; 2017 Jan; 40(1):69-76. PubMed ID: 27797925 [TBL] [Abstract][Full Text] [Related]
11. Saxagliptin affects long-bone microarchitecture and decreases the osteogenic potential of bone marrow stromal cells. Sbaraglini ML; Molinuevo MS; Sedlinsky C; Schurman L; McCarthy AD Eur J Pharmacol; 2014 Mar; 727():8-14. PubMed ID: 24485890 [TBL] [Abstract][Full Text] [Related]
12. Saxagliptin versus glipizide as add-on therapy to metformin: assessment of hypoglycemia. Mintz ML; Minervini G Curr Med Res Opin; 2014 May; 30(5):761-70. PubMed ID: 24397584 [TBL] [Abstract][Full Text] [Related]
13. Saxagliptin: a new drug for the treatment of type 2 diabetes. Thareja S; Aggarwal S; Malla P; Haksar D; Bhardwaj TR; Kumar M Mini Rev Med Chem; 2010 Jul; 10(8):759-65. PubMed ID: 20402634 [TBL] [Abstract][Full Text] [Related]
14. Frequency of cancer events with saxagliptin in the SAVOR-TIMI 53 trial. Leiter LA; Teoh H; Mosenzon O; Cahn A; Hirshberg B; Stahre CA; Hoekstra JB; Alvarsson M; Im K; Scirica BM; Bhatt DL; Raz I; Diabetes Obes Metab; 2016 Feb; 18(2):186-90. PubMed ID: 26443993 [TBL] [Abstract][Full Text] [Related]
15. Effects of saxagliptin add-on therapy to insulin on blood glycemic fluctuations in patients with type 2 diabetes: A randomized, control, open-labeled trial. Li FF; Jiang LL; Yan RN; Zhu HH; Zhou PH; Zhang DF; Su XF; Wu JD; Ye L; Ma JH Medicine (Baltimore); 2016 Oct; 95(43):e5229. PubMed ID: 27787387 [TBL] [Abstract][Full Text] [Related]
16. Overcoming bioanalytical challenges in an Onglyza(®) intravenous [(14)C]microdose absolute bioavailability study with accelerator MS. Xu XS; Dueker SR; Christopher LJ; Lohstroh PN; Keung CF; Cao KK; Bonacorsi SJ; Cojocaru L; Shen JX; Humphreys WG; Stouffer B; Arnold ME Bioanalysis; 2012 Aug; 4(15):1855-70. PubMed ID: 22943617 [TBL] [Abstract][Full Text] [Related]
17. Effects of saxagliptin added to sub-maximal doses of metformin compared with uptitration of metformin in type 2 diabetes: the PROMPT study. Hermans MP; Delibasi T; Farmer I; Lohm L; Maheux P; Piatti P; Malvolti E; Jörgens S; Charbonnel B Curr Med Res Opin; 2012 Oct; 28(10):1635-45. PubMed ID: 23020253 [TBL] [Abstract][Full Text] [Related]
18. Dipeptidyl peptidase-4 inhibition prevents cell death via extrinsic and intrinsic apoptotic pathways in rat pancreas with insulin resistance. Nephan G; Coskun ZM; Bolkent S Cell Biochem Funct; 2018 Jun; 36(4):212-220. PubMed ID: 29748970 [TBL] [Abstract][Full Text] [Related]
19. Amino acid conjugated chitosan nanoparticles for the brain targeting of a model dipeptidyl peptidase-4 inhibitor. Fernandes J; Ghate MV; Basu Mallik S; Lewis SA Int J Pharm; 2018 Aug; 547(1-2):563-571. PubMed ID: 29906562 [TBL] [Abstract][Full Text] [Related]
20. Saxagliptin, a potent, selective inhibitor of DPP-4, does not alter the pharmacokinetics of three oral antidiabetic drugs (metformin, glyburide or pioglitazone) in healthy subjects. Patel CG; Kornhauser D; Vachharajani N; Komoroski B; Brenner E; Handschuh del Corral M; Li L; Boulton DW Diabetes Obes Metab; 2011 Jul; 13(7):604-14. PubMed ID: 21332626 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]